Comparative Pharmacology
Head-to-head clinical analysis: ANZUPGO versus DEPOCYT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANZUPGO versus DEPOCYT.
ANZUPGO vs DEPOCYT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not established; no known pharmacological mechanism due to lack of clinical data.
Cytarabine is a nucleoside analog that inhibits DNA polymerase, leading to termination of DNA chain elongation and cell death in the S phase of the cell cycle.
Not available. ANZUPGO is not a recognized drug in medical literature.
50 mg intrathecally via lumbar puncture or intraventricularly via Ommaya reservoir on days 1, 15, 29, 43, 57, 71, 85, and 99 for induction; followed by consolidation and maintenance doses. Administer with dexamethasone 4 mg PO/IV twice daily for 5 days starting on the day of DepoCyt injection.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours; clinically, this supports intravenous administration every 6-8 hours for continuous coverage.
After intrathecal administration, the terminal half-life of cytarabine in CSF is 2.5-4.5 hours (mean 3.5 hours) due to slow clearance from CSF; systemic half-life is 10-15 minutes due to rapid deamination.
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination constitutes the remainder (20-30%).
Renal excretion of cytarabine metabolites accounts for >70% of elimination; unchanged cytarabine excretion is minimal (<10%). Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Antineoplastic
Antineoplastic